A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

BACKGROUND: Olaparib is an oral poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic with activity against VEGFR-1, 2, and 3. Both agents have antitumor activity in women with recurrent ovarian cancer, and the combination of these agents was active and had manageable toxici...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Liu, Joyce F., Barry, William T., Birrer, Michael, Lee, Jung-Min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, BJ, Buss, Mary K., Nattam, Sreenivasa, Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Whalen, Christin, Obermayer, Lisa, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294183/
https://ncbi.nlm.nih.gov/pubmed/25218906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70391-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados